75/100B48.560
USD
0.12
(0.25%)
Market Open
Last updated: · Delayed 15 min
Fair value81.88Plus-41%61Price 48.56102
Q4 FY2026 · Earnings report
EPS estimate 0.94Revenue estimate 14.43B
Q4 FY2026 · Earnings report
EPS estimate 0.94Revenue estimate 14.43B
If you had invested in Sanofi ADS ago, it would be worth $1,754 today, against $4,096 in SPY and $6,368 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
75/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation6.7
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Sanofi ADS key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Dividend stock · 7.0/10Growth 2.8 · Value 1.0 · Dividend 7.0
- Day range
- 48.310 – 48.650
- 52-week range
- 39.070 – 52.680
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 116.36B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 74.49
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 4.37
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 0.65
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 4.98%
- EPS growth forecast (FY2026)
- +2.6%
- Volume
- 3,960
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.28
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 61.7/100Environment 61 · Social 68 · Governance 56
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Belén Garijo López
- Employees
- 76K
- Website
- sanofi.com
- IPO date
- 1 Jul 2002
Sanofi ADS earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
0.94 USD
Revenue estimate
14.43B USD
Last quarter · Q3 FY2026
EPS2.04Beat +25.2%Revenue17.02BBeat +18.9%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 1.12 | — | — | +2.06% | 12.20B | — | — | -5.75% | |
| Q4 FY2026 | 0.94 | — | — | +5.62% | 14.43B | — | — | +0.65% | |
| Q3 FY2026 | 1.63 | 2.04 | +25.15% | +20.00% | 14.31B | 17.02B | +18.87% | +10.31% | |
| Q2 FY2026 | 1.10 | 1.21 | +10.00% | +34.44% | 15.34B | 14.06B | -8.33% | +11.23% | |
| Q1 FY2026 | 1.06 | 1.10 | +3.77% | +17.02% | 12.68B | 12.94B | +2.09% | +11.31% | |
| Q4 FY2025 | 0.84 | 0.89 | +5.95% | +27.14% | 11.71B | 14.34B | +22.38% | +81.42% | |
| Q3 FY2025 | 1.60 | 1.70 | +6.25% | +8.28% | 11.11B | 15.43B | +38.89% | -0.65% | |
| Q2 FY2025 | 0.96 | 0.90 | -6.25% | -3.23% | 12.36B | 12.64B | +2.28% | +3.30% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2027 | 4.84 | — | — | +6.55% | 55.87B | — | — | +6.30% |
| FY2026 | 4.55 | — | — | +2.62% | 52.56B | — | — | -2.71% |
| FY2025 | 4.53 | 4.43 | -2.17% | +6.24% | 52.97B | 54.03B | +2.01% | +13.48% |
| FY2024 | 3.82 | 4.17 | +9.21% | -5.01% | 45.49B | 47.61B | +4.66% | -23.24% |
| FY2023 | 4.43 | 4.39 | -0.99% | +1.62% | 49.22B | 62.02B | +26.03% | +30.50% |
| FY2022 | 4.40 | 4.32 | -1.77% | +11.34% | 47.59B | 47.53B | -0.14% | +4.32% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Sanofi ADS analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
53.00 USD
+9.14%
Analysts' 1-year price targets range from 49.00 to 57.00, with an average of 53.00.
Past year
1-year forecast
Strong sellStrong buy
Hold
7 ratings
| Buy | 0 | |
| Hold | 7 | |
| Sell | 0 |
12-month price target
| Highest target | 57.00 |
| Average target | 53.00 |
| Lowest target | 49.00 |
| Current price | 48.56 |
Sanofi ADS valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 74.49
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 10.68
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 2.07
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 1.44
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 7.66
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
116.36B USD
+
Total debt
21.93B USD
−
Cash and short-term investments
6.59B USD
=
Enterprise value
131.69B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Sanofi ADS against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Bristol-Myers Squibb, Pfizer, Gilead Sciences, Amgen, Biogen, and Merck & Co., the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median74.510.183.1
- Gross marginHighest in 5 years72.1%68.7%72.1%Against its peers: 3 of 7Peers' median 71.5%
- Operating marginAt its median20.5%16.4%25.1%Against its peers: 6 of 7Peers' median 28.8%
- Net marginAbove its median16.7%12.6%20.6%Against its peers: 4 of 7Peers' median 17.8%
- Return on equityAbove its median10.9%7.2%11.2%Against its peers: 5 of 7Peers' median 36.1%
- Free cash flow marginAt its median18.8%13.3%21.6%Against its peers: 6 of 7Peers' median 21.5%
- Revenue growthAbove its median5.5%2.6%6.4%Against its peers: 2 of 7Peers' median 1.3%
- EPS growthHighest in 5 years46.1%-49.3%46.1%Against its peers: 3 of 6Peers' median 8.0%
- Debt to EBITDAAt its median1.63×1.57×1.94×Against its peers: 1 of 7Peers' median 2.73×
- Current ratioLowest in 5 years1.091.091.46Against its peers: 7 of 7Peers' median 1.40
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Sanofi ADS growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 50.98B EUR
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 4.18B EUR
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 73.68%
- Operating margin
- 16.32%
- Net margin
- 8.19%
Revenue / Net income
Revenue Net income Net margin
Sanofi ADS revenue breakdown
By region
FY2025
76.4%Reportable Geographical Zones16.1%Europe4.6%China3.0%France
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Reportable Geographical Zones | 43.63B | 76.4% | +1.3% |
| Europe | 9.17B | 16.1% | -11.8% |
| China | 2.62B | 4.6% | — |
| France | 1.71B | 3.0% | -28.1% |
How Sanofi ADS makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revenue46.72B 100.0%
Cost of revenue13.05B 27.9%
Gross profit33.67B 72.1%
Research and development7.84B 16.8%
Selling and administration10.24B 21.9%
Other operating expenses5.99B 12.8%
Operating income9.60B 20.5%
Tax1.04B 2.2%
Other expense741.00M 1.6%
Net income7.81B 16.7%
FY2025, in EUR. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in EUR. Each band is as wide as its money; the percentage is its share of revenue.
Sanofi ADS dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 2.42 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 4.98%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 371.04%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 4
- Frequency
- Annual
- Last payment
- 2.42 USD
- Last ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 4 May 2026
- Last payment date
- 3 Jun 2026
Dividends per share
Sanofi ADS financial health
- Cash and short-term investments
- 5.97B EUR
- Total debt
- 19.85B EUR
- Net cash
- -13.88B EUR
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.12
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.27
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 8 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 1.77
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Sanofi ADS ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 7.93%
- Institutional holders
- 742 (-22)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 90.18%
Who owns the shares
Institutions 7.9% Others 92.1%
As of 30 Jun 2026
Shares free to trade
Free float 2.16B shares ·90.2% Closely held 235.20M shares ·9.8%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: Sanofi ADS
Sector: Healthcare
Industry: Drug Manufacturers - General
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.